Endocrine Therapies for Patients with Recurrent Breast Cancer: Predictive Factors for Responses to First- and Second-Line Endocrine Therapies

Publisher： Karger

E-ISSN： 1423-0232|59|1|31-37

ISSN： 0030-2414

Source： Oncology, Vol.59, Iss.1, 2000-11, pp. : 31-37

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

By  

Oncology, Vol. 83, Iss. 2, 2012-07 ,pp. : 101-107

Karger

Access to resources Recommend Favorite

Endocrine Therapies and QTc Prolongation

By  

Current Drug Safety, Vol. 5, Iss. 1, 2010-01 ,pp. : 79-84

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: Efficacy in First- and Second-Line Therapy of Advanced Breast Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 1-3

Karger

Access to resources Recommend Favorite

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-04 ,pp. : 131-136

Karger

Access to resources Recommend Favorite

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite